WSE:POM

Stock Analysis Report

Executive Summary

Polmed S.A. provides medical services to private and institutional clients.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.

Risks

  • Polmed is not covered by any analysts.

Share Price & News

How has Polmed's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

WSE:POM

2.5%

PL Healthcare

0.6%

PL Market


1 Year Return

16.5%

WSE:POM

10.7%

PL Healthcare

-9.5%

PL Market

POM outperformed the Healthcare industry which returned -3.1% over the past year.

POM outperformed the Market in Poland which returned -9.3% over the past year.


Share holder returns

POMIndustryMarket
7 Day0%2.5%0.6%
30 Day0%2.8%-8.2%
90 Day-0.7%7.1%-4.0%
1 Year16.5%16.5%12.9%10.7%-6.6%-9.5%
3 Year11.3%1.4%4.2%-1.6%9.0%0.9%
5 Year27.5%11.5%55.3%44.7%-0.3%-13.1%

Price Volatility Vs. Market

How volatile is Polmed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Polmed undervalued based on future cash flows and its price relative to the stock market?

9.27x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Polmed to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Polmed to establish if it is available at substantial discount.


Price Based on Earnings

Polmed is good value based on earnings compared to the PL Healthcare industry average.

Polmed is good value based on earnings compared to the Poland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Polmed, we can't assess if its growth is good value.


Price Based on Value of Assets

Polmed is good value based on assets compared to the PL Healthcare industry average.


Next Steps

Future Growth

How is Polmed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

5.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Polmed is high growth as no revenue estimate data is available.

Polmed's earnings are expected to grow by 5.6% yearly, however this is not considered high growth (20% yearly).

Unable to compare Polmed's revenue growth to the Poland market average as no estimate data is available.

Polmed's earnings growth is positive but not above the Poland market average.

Polmed's earnings growth is expected to exceed the low risk savings rate of 3.3%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Polmed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Polmed performed over the past 5 years?

27.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Polmed has delivered over 20% year on year earnings growth in the past 5 years.

Polmed's 1-year earnings growth exceeds its 5-year average (125.7% vs 27.7%)

Polmed's earnings growth has exceeded the PL Healthcare industry average in the past year (125.7% vs 81.4%).


Return on Equity

Polmed has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Polmed used its assets more efficiently than the PL Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Polmed has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Polmed's financial position?


Financial Position Analysis

Polmed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Polmed's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Polmed's level of debt (7.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (37.5% vs 7.3% today).

Debt is well covered by operating cash flow (62.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 198.4x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 7.9x debt.


Next Steps

Dividend

What is Polmed's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Polmed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Polmed's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Polmed has not reported any payouts.

Unable to verify if Polmed's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Polmed has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Polmed's salary, the management and board of directors tenure and is there insider trading?

zł479k

CEO Compensation


CEO

Radoslaw Szubert 0

0.0yrs

Tenure

zł479,000

Compensation

Mr. Radosaw Szubert serves as the Chairman of the Board at Polmed S.A. 


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Radoslaw Szubert

    Chairman of the Board

    • Tenure: 0.0yrs
    • Compensation: zł479.00k
  • Romuald Magdon

    Vice President of the Board of Directors

    • Tenure: 0.0yrs
    • Compensation: zł479.00k
  • Katarzyna Plit-Muszynska

    Sales Director

    • Tenure: 0.0yrs
  • Alicja Czechowska

    Financial Director

    • Tenure: 0.0yrs
  • Grazyna Fijal

    Staff Director

    • Tenure: 0.0yrs
  • Grazyna Jendyk

    Manager of the Board of Directors Office

    • Tenure: 0.0yrs
  • Dorota Cerowska

    Chief Accountant

    • Tenure: 0.0yrs

Board Members

  • Krzysztof Plachta (59yo)

    Chairperson of the Supervisory Board

    • Tenure: 0.0yrs
    • Compensation: zł5.00k
  • Robert Bozyk

    Vice Chairperson of the Supervisory Board

    • Tenure: 0.0yrs
  • Monika Gaszewska

    Vice President of the Supervisory Board

    • Tenure: 0.0yrs
    • Compensation: zł4.00k
  • Tomasz Polakowski

    Member of Supervisory Board

    • Tenure: 0.0yrs
    • Compensation: zł3.00k
  • Boleslaw Rutkowski

    Member of the Supervisory Board

    • Tenure: 0.0yrs
  • Jacek Dudkiewicz

    Member of Supervisory Board

    • Tenure: 0.0yrs
    • Compensation: zł4.00k

Company Information

Polmed S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Polmed S.A.
  • Ticker: POM
  • Exchange: WSE
  • Founded: 1999
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: zł46.654m
  • Shares outstanding: 16.09m
  • Website: https://www.polmed.pl

Number of Employees


Location

  • Polmed S.A.
  • Os.Kopernika 21
  • Starogard Gdanski
  • 83-200
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
POMWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNDec 2010
0Q3OLSE (London Stock Exchange)YesCommon Bearer SharesGBPLNDec 2010

Biography

Polmed S.A. provides medical services to private and institutional clients. The company offers services, including basic and specialist medical care, full medical diagnostics, rehabilitation, dentistry, ae ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/11/27 19:06
End of Day Share Price2018/09/21 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.